TY - JOUR
T1 - P3 mAb
T2 - An immunogenic anti-NeuGcGM3 antibody with unusual immunoregulatory properties
AU - Martínez, Darel
AU - Rondón, Nely Rodríguez
AU - Griñán, Tania
AU - Rondón, Teresa
AU - Vázquez, Ana María
AU - Pérez, Rolando
AU - Hernández, Ana María
PY - 2012
Y1 - 2012
N2 - P3 is a murine IgM mAb that recognize N-glycosylated gangliosides, sulfatides, and anti- gens expressed in melanoma, breast, and lung human tumors.This antibody has the ability to trigger an IgG antibody response in the syngeneic BALB/c model, even when it is admin- istered in the absence of adjuvant or carrier protein.The mechanism by which the P3 mAb, a self-immunoglobulin, induce this immune response in the absence of co-stimulatory or classical danger signals is still unknown. In the present paper we show that the high immunogenicity of P3 mAb depends not only on CD4 but also on CD8+ T cells, since the depletion of CD8+ or CD4+ T cells led to the loss of P3 mAb immunogenicity in the syngeneic model. Furthermore, the immunization with P3 mAb enhanced the recovery of the CD8+ T cell population in mice treated with an anti-CD8a antibody. Additionally, the immunization with P3 mAb restored the capacity of immunosuppressed mice to reject allogeneic tumors, a mechanism mediated by the action of CD8+ T cells. Finally, in mice with cyclophosphamide induced lymphopenia, the administration of P3 mAb accelerated the recovery of both CD4+ and CD8+ T cells. These results show new possibilities for B and CD8+ T cells interactions during the immune response elicited by a self-protein. Fur- thermore they point to P3 mAb as a potential interesting candidate for the treatment of immunosuppressed patients.
AB - P3 is a murine IgM mAb that recognize N-glycosylated gangliosides, sulfatides, and anti- gens expressed in melanoma, breast, and lung human tumors.This antibody has the ability to trigger an IgG antibody response in the syngeneic BALB/c model, even when it is admin- istered in the absence of adjuvant or carrier protein.The mechanism by which the P3 mAb, a self-immunoglobulin, induce this immune response in the absence of co-stimulatory or classical danger signals is still unknown. In the present paper we show that the high immunogenicity of P3 mAb depends not only on CD4 but also on CD8+ T cells, since the depletion of CD8+ or CD4+ T cells led to the loss of P3 mAb immunogenicity in the syngeneic model. Furthermore, the immunization with P3 mAb enhanced the recovery of the CD8+ T cell population in mice treated with an anti-CD8a antibody. Additionally, the immunization with P3 mAb restored the capacity of immunosuppressed mice to reject allogeneic tumors, a mechanism mediated by the action of CD8+ T cells. Finally, in mice with cyclophosphamide induced lymphopenia, the administration of P3 mAb accelerated the recovery of both CD4+ and CD8+ T cells. These results show new possibilities for B and CD8+ T cells interactions during the immune response elicited by a self-protein. Fur- thermore they point to P3 mAb as a potential interesting candidate for the treatment of immunosuppressed patients.
KW - CD8T cells
KW - Immunogenicity
KW - Immunoregulation
KW - Monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=84874159213&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2012.00094
DO - 10.3389/fimmu.2012.00094
M3 - Article
AN - SCOPUS:84874159213
SN - 1664-3224
VL - 3
JO - Frontiers in Immunology
JF - Frontiers in Immunology
IS - APR
M1 - Article 94
ER -